305 related articles for article (PubMed ID: 18031950)
21. Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue.
Reinicke K; Sotomayor P; Cisterna P; Delgado C; Nualart F; Godoy A
J Cell Biochem; 2012 Feb; 113(2):553-62. PubMed ID: 21938742
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis.
Matsuyama M; Hayama T; Funao K; Kawahito Y; Sano H; Takemoto Y; Nakatani T; Yoshimura R
Oncol Rep; 2007 Jul; 18(1):99-104. PubMed ID: 17549353
[TBL] [Abstract][Full Text] [Related]
23. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia.
Monsef N; Soller M; Isaksson M; Abrahamsson PA; Panagopoulos I
Prostate; 2009 Jun; 69(9):909-16. PubMed ID: 19274762
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical characterization of canine prostatic intraepithelial neoplasia.
Matsuzaki P; Cogliati B; Sanches DS; Chaible LM; Kimura KC; Silva TC; Real-Lima MA; Hernandez-Blazquez FJ; Laufer-Amorim R; Dagli ML
J Comp Pathol; 2010 Jan; 142(1):84-8. PubMed ID: 19643431
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of MSX2 in nodular hyperplasia, high-grade prostatic intraepithelial neoplasia and prostate adenocarcinoma.
Chua CW; Chiu YT; Yuen HF; Chan KW; Wang X; Ling MT; Wong YC
APMIS; 2010 Dec; 118(12):918-26. PubMed ID: 21091772
[TBL] [Abstract][Full Text] [Related]
26. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells.
De Marzo AM; Meeker AK; Epstein JI; Coffey DS
Am J Pathol; 1998 Sep; 153(3):911-9. PubMed ID: 9736039
[TBL] [Abstract][Full Text] [Related]
27. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma.
Chandler JD; Williams ED; Slavin JL; Best JD; Rogers S
Cancer; 2003 Apr; 97(8):2035-42. PubMed ID: 12673735
[TBL] [Abstract][Full Text] [Related]
28. Prostatic basal cells in the peripheral and transitional zones: zonal variation in morphology and in immunophenotype.
Garcia FU; Haber MM; Chen X
Prostate; 2007 Nov; 67(15):1686-92. PubMed ID: 17879949
[TBL] [Abstract][Full Text] [Related]
29. Androgen receptor as a potential sign of prostate cancer metastasis.
Lévesque MH; El-Alfy M; Cusan L; Labrie F
Prostate; 2009 Nov; 69(15):1704-11. PubMed ID: 19670238
[TBL] [Abstract][Full Text] [Related]
30. [Detection of AMACR (P504S), P63 and 34betaE12 cocktail in the early diagnosis of prostate cancer].
Yu T; Zhu SX; Zheng S; Chen SP
Zhonghua Nan Ke Xue; 2007 Mar; 13(3):222-5. PubMed ID: 17393784
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10 and MUC-2 presence and expression in prostate carcinogenesis.
Cappello F; Rappa F; David S; Anzalone R; Zummo G
Anticancer Res; 2003; 23(2B):1325-31. PubMed ID: 12820390
[TBL] [Abstract][Full Text] [Related]
32. Loss of annexin II heavy and light chains in prostate cancer and its precursors.
Chetcuti A; Margan SH; Russell P; Mann S; Millar DS; Clark SJ; Rogers J; Handelsman DJ; Dong Q
Cancer Res; 2001 Sep; 61(17):6331-4. PubMed ID: 11522620
[TBL] [Abstract][Full Text] [Related]
33. Upregulation of erythropoietin receptor in human prostate carcinoma and high-grade prostatic intraepithelial neoplasia.
Zhou T; Xu C; He M; Sun Y
Prostate Cancer Prostatic Dis; 2008; 11(2):143-7. PubMed ID: 17637760
[TBL] [Abstract][Full Text] [Related]
34. Unfavorable prognostic value of human PEDF decreased in high-grade prostatic intraepithelial neoplasia: a differential proteomics approach.
Qingyi Z; Lin Y; Junhong W; Jian S; Weizhou H; Long M; Zeyu S; Xiaojian G
Cancer Invest; 2009 Aug; 27(7):794-801. PubMed ID: 19637042
[TBL] [Abstract][Full Text] [Related]
35. The effect of oxytocin on cell proliferation in the human prostate is modulated by gonadal steroids: implications for benign prostatic hyperplasia and carcinoma of the prostate.
Whittington K; Connors B; King K; Assinder S; Hogarth K; Nicholson H
Prostate; 2007 Jul; 67(10):1132-42. PubMed ID: 17492653
[TBL] [Abstract][Full Text] [Related]
36. Immunoreactivity to caspase-3, caspase-7, caspase-8, and caspase-9 forms is frequently lost in human prostate tumors.
Rodríguez-Berriguete G; Galvis L; Fraile B; de Bethencourt FR; Martínez-Onsurbe P; Olmedilla G; Paniagua R; Royuela M
Hum Pathol; 2012 Feb; 43(2):229-37. PubMed ID: 21802116
[TBL] [Abstract][Full Text] [Related]
37. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue.
Hamdy FC; Autzen P; Robinson MC; Horne CH; Neal DE; Robson CN
Cancer Res; 1997 Oct; 57(19):4427-31. PubMed ID: 9331107
[TBL] [Abstract][Full Text] [Related]
38. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
Tavora F; Epstein JI
Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
[TBL] [Abstract][Full Text] [Related]
39. p63 expression profile in normal and malignant prostate epithelial cells.
Davis LD; Zhang W; Merseburger A; Young D; Xu L; Rhim JS; Moul JW; Srivastava S; Sesterhenn IA
Anticancer Res; 2002; 22(6C):3819-25. PubMed ID: 12553000
[TBL] [Abstract][Full Text] [Related]
40. Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate tumor.
Lee S; Desai KK; Iczkowski KA; Newcomer RG; Wu KJ; Zhao YG; Tan WW; Roycik MD; Sang QX
Cell Res; 2006 Sep; 16(9):750-8. PubMed ID: 16940965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
